Adalimumab ameliorates abdominal aorta cross clamping which induced liver injury in rats

Abstract

The aim of this study was to investigate the possible protective effects of adalimumab (ADA) on cell damage in rat liver tissue during ischemia/reperfusion (I/R) injury of infrarenal abdominal aorta. Thirty male Wistar-albino rats were divided into three groups: control, I/R, and I/R+ADA, each group containing 10 animals. Laparotomy without I/R injury was performed in the control group animals. Laparotomy in the I/R group was followed by two hours of infrarenal abdominal aortic cross ligation and then two hours of reperfusion. ADA (50 mg/kg) was administered intraperitoneally as a single dose, to the I/R+ADA group, five days before I/R. The tumor necrosis factor-alpha (TNF-α) (pg/mg protein) and nitric oxide (NO) (µmol/g protein) levels in the I/R group (430.8 ± 70.1, 8.0 ± 1.1, resp.) were significantly higher than those in the I/R+ADA group (338.0 ± 71.6, P = 0.006; 6.3 ± 1.2, P = 0.008) and the control group (345.5 ± 53.3, P = 0.008; 6.5 ± 1.5, P = 0.010, resp.). I/R causes severe histopathological injury to the liver tissue, but ADA leads to much less histopathological changes. ADA treatment significantly decreased the severity of liver I/R injury. ADA pretreatment may have protective effects on experimental liver injury.

Figure 1

Histopathologic examination of liver tissue by light microscopy; (a) control group, (b) I/R applied group, di: dilatation and v: vacuolization, (c) I/R+ADA applied group, de: degenerative cell, H&E stain.

Figure 2

Histopathologic examination of liver tissue by light microscopy; immunohistochemical staining of liver tissues with immunoperoxidase method revealed strong and diffuse reactivity; (a) control group, (b) I/R applied group, (c) I/R+ADA applied group, immunoperoxidase stained Antiliver arginase antibody.

Figure 3

Histopathologic examination of liver tissue by light microscopy; immunohistochemical staining of liver tissues with immunoperoxidase method revealed strong and diffuse reactivity; (a) control group (b) I/R applied group, (c) I/R+ADA applied group, immunoperoxidase stained Anti-CPS1 antibody.